Ready to donate?

You can make and manage your appointments online

Make appointment now

or

You can call us on

13 14 95

Our collaborators 2016-2017

We collaborate widely with health professionals, academics and industry both in Australia and abroad. This table shows our collaborators in 2016-2017:

Institution

Research area and Project

Collaborator(s)

Universities

Australian National University

Product safety: Novel red cell targets for biopharmaceuticals.

Prof. Simon Foote, Dr Brendan McMorran, Dr Gaétan Burgio

James Cook University

Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, CHIKV, LNV etc.): disease burden and consequences for blood supply safety

Prof. John McBride

Monash University

Product usage: Transfusion Outcomes Research Collabrative (TORC).

Prof. J Mc Neill and members of the TORC Steering committee

Murdoch University

Product safety: Red cell storage duration and procoagulant effects: Role of microparticles and smaller particles.

Ross Baker and Quentin Hughes

Queensland University of Technology

Product safety: Red cell alloimmunisation: How can extended genotyping support the ongoing transfusion needs of haemoglobinopathy patients?

Prof. Louise Hafner

 

Product safety: reducing the risk of TRALI.

Prof. Adrian Barnett, Anne-Marie Christensen

 

Donor behaviour: Hospitals to Hospitality: Understanding the influence of Interaction with staff and service quality on donor intention to donate.

Prof. Rebekah Russell-Bennett

 

Product safety: Points of structural failure that may lead to storage-related changes of red cells.

Prof YT Gu, Dr E Sauret, Dr S Saha and Prof Y Xiao, Sarah Barns, Dr Alex Stilgoe

 

Product safety: What is the risk of alloimmunisation by transfusion of variant RhD red blood cells that serotype as RhD Negative?

Christine Knauth

 

Product safety: Is parvovirus B19 a concern for the blood safety in Australia?

Dr Francesca Frentiu

 

Product safety: Red cell storage duration and procoagulant effects: Role of microparticles and smaller particles.

Dr Natalie Pecheniuk

University of Newcastle

Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety?

Prof. Stephen Graves

University of NSW

Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety?

Dr Heather Gidding

 

Donor behaviour: Emotional Psychology of Blood Donors.

Dr Lisa Williams

 

Product develoment and storage: Biomimetic blood bag materials for prolonged platelet storage.

Prof. John Whitelock, Dr Megan Lord, Dr Brooke Farrugia

University of Queensland

Product safety: Reducing the risk of TRALI.

Prof. Michael Reade

 

Donor Behaviour: multiple projects.

A/Prof. Barbara Masser (co-appointment)

 

Product safety: Inactivation of Zika virus in plasma and in platelet concentrates following treatment with the THERAFLEX pathogen inactivation (PI) technologies.

Prof Roy Hall, Dr Jody Hobson Peters, Dr Daniel Watterson, Prof Paul Young

 

Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, CHIKV, LNV etc.):disease burden and consequences for blood supply safety.

Prof. John Aaskov,  Prof. Roy Hall (UQ), Dr Helle Bielefeldt-Ohman, Dr John Wright, Dr Jasimme Uddin

 

Donor behaviour: Hospitals to Hospitality: Understanding the influence of Interaction with staff and service quality on donor intention to donate.

Dr Josephine Peevite

 

Product safety: Novel red cell targets for biopharmaceuticals.

Dr Benjamin Shultz

University of South Australia

Product safety: Chikungunya and/or Zika virus emergence and establishment in Australia.

A/Prof Craig Williams, Gina Mincham

University of Sydney

Donor Behaviour: Behavioural economics to understand blood donations.

Evarn Ooi co-appointment with Prof. Robert Slonim

 

Centre for Values, Ethics and the Law in Medicine: APPRISE partner.

Prof. Angus Dawson

 

Product development and storage: Development and characterisation of platelet lysate.

Dr Zufu Lu

University of Technology Sydney

Donor health and wellbeing: biostatistics, several projects.

Louise Ryan
Dr Stephen Wright (co-appointment)

 

Product development and storage: Characterisation of cryopreserved platelets. Product development and storage: Cold storage of platelets.

Dr Matthew Padula

 

Institution

Research area and Project

Collaborator(s)

Hospitals

Canberra Hospital

Product safety: Investigating levels of BRMs in donors implicated in clinical cases of TRALI.

Prof. Matthew Cook, Dr Zuopeng Wu

Concord Repatriation and General Hospital

Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk?

Prof Peter Maitz , Dr Rosalba Cross

Flinders Medical Centre

The incidence of microchimerism in chronically transfused patients.

A/Prof. David Roxby

Gosford Hospital

Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk?

Dr Duncan Reed

John Hunter Hospital

Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk?

Prof. Zsolt Balogh

Mater Mothers’ Hospital Brisbane

Product usage: The incidence of microchimerism in paediatric patients.

Dr Bryony Ross

 

Product safety: Reduction in anti-D immunoglobulin usage by genotyping: a cost (and) benefit analysis.

Dr Glen Gardener

Orange Health Service

Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk?

Dr Doug Lenton, A/Prof Brian Burns

Prince Charles Hospital

Product safety: Reducing the risk of TRALI and Reducing the risks associated with transfusion.

Prof John Fraser and the Prince Charles Hospital Critical Care Research Group

 

Product safety: Transfusion associated immunomodulation in a cohort of cardiac patients – translating laboratory findings to a clinical context.

Dr Rishendran Naidoo and Prof John Fraser

Prince of Wales Hospital

Product usage: An open label, single arm clinical trial assessing the safety and efficacy of allogeneic 20% serum eye drops in severe dry eye patients.

Prof Minas Coroneo

Royal Melbourne Hospital

Product usage: The incidence of microchimerism in chronically transfused patients.

Dr Chris Ward, Dr Lesley Survela

Royal North Shore Hospital

Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk?

Dr Tony Joseph, Dr Mark Gillett, Dr Lesley Survela

 

Product safety: Red cell alloimmunisation: How can extended genotyping support the ongoing transfusion needs of haemoglobinopathy patients?

Prof Chris Ward

 

Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting.

Prof James Isbister, Dr Jennifer
Bowen, Dr Eleni Mayson

Royal Perth Hospital

Product development and storage: Development and characterisation of platelet lysates.

Dr Marian Sturm and Dr Leon Brownrigg

 

Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing

A/Prof. Timothy Day, Prof. Lynettte Kiers

Royal Prince Alfred  Hospital

Product safety: Reduction in anti-D immunoglobulin usage by genotyping: a cost (and) benefit analysis.

Clin Prof. Jonathon Hyett

 

Product Safety: Non-invasive assessment (NIPA) translation: for high risk pregnant women who are allo-immunised to the RhD blood group antigen.

Clin Prof. Jonathon Hyett

 

Product development and storage: Development and characterisation of platelet lysate.

Dr Janet McPherson and Dr James Favaloro

St George Hospital

Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk?

Dr Mary Langcake

Sydney Eye Hospital

Product development and storage: Development and characterisation of platelet lysate.

Simon Cooper

Westmead Hospital

Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk?

Dr Jeremy Hsu, Dr Leonardo Pasalic

 

Institution

Research area and Project

Collaborator(s)

Government Health Departments and Agencies

Clinical Excellence Commission, NSW

Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting.

Dr Amanda Thomson

Hunter New England Health

Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety?

Prod. David Durrheim

National Centre for Immunisation research and surveillance

Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety?

Dr NIck Wood, Dr Helen Quinn, Prof. Peter McIntyre

National Blood Transfusion Committee

To review the use of O negative red cells, cryoprecipitate and washed cells nationally

 

NSW Office of Kids and Families

Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting.

Associate Professor Michael Nicholl

Queensland Health

Product safety: Q fever: how common is it, who is at risk and what does this mean for blood safety?

Dr Penny Hutchison

 

Product safety: Transfusion Transmitted Infections and Emerging Risks - Chikungunya and/or Zika virus emergence and establishment in Australia.

Cassie Jansen, Brian Montgomery

SA Pathology

Product safety: Red cell alloimmunisation: How can extended genotyping support the ongoing transfusion needs of haemoglobinopathy patients?

A/Prof. David Roxby

 

Institution

Research area and Project

Collaborator(s)

Research Institutes

ARC Centre of Excellence for Mathematical & Statistical Frontiers (ACEMS)

Donor Health and Wellbeing: 45 and Up: Blood Service data linkage project: a world-class donor health data-asset.
Donor Health and Wellbeing: Safety and feasibility of first appointment plasmapheresis donation.

Prof. Louise Ryan

Australian Genome Research Facility

Product safety: Genetic basis for blood groups.

 

Centre for Biopharmaceutical Innovation

Product safety: Novel red blood cell targets for biopharmaceuticals.

Professor Steven Mahler, Dr Xuan Bui

Centre for Children’s Health Research

Product safety: Is parvovirus B19 a concern for blood safety in Australia?

Dr Sarah Tozer, Seweryn Bialasiewicz

Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead

Product safety: APPRISE partner.

Prof Lyn Gilbert

Mater Medical Research Institute

Product Safety: Non-invasive assessment (NIPA) translation: for high risk pregnant women who are allo-immunised to the RhD blood group antigen.

Dr Glenn Gardener, Anne Tremellen

National Centre for Immunisation Research and Surveillance

Product safety: Q fever: how common is it, who is at risk and what does this mean for blood safety?

Dr Nick Wood, Dr Helen Quinn, Prof. Peter McIntyre

Perth Blood Institute

Product safety:red cell storage duration and procoagulant effects: Role of microparticles and smaller particles

Ross Baker and Quentin Hughes

Queensland Institute of Medical Research-Berghofer Medical research institute

Product safety: Detection of Ross River virus in Australian blood donations.

Dr Natalie Prow

 

Product safety: Exotic mosquito-borne virus threats to Australia (including WNV,
CHIKV, LNV etc.):disease burden and consequences for blood supply safety.

Prof Andreas Suhrbier, Dr Greg Devine

 

Product safety: Reduction in anti-D immunoglobulin usage by genotyping: a cost (and) benefit analysis.

Dr Louisa Gordon

Save Sight Institute

Product usage: An open label, single arm clinical trial assessing the safety and efficacy of allogeneic 20% serum eye drops in severe dry eye patients

Dr Con Petsoglou

Sax Institute

Donor Health and Wellbeing:  45 and up study: Blood Service data linkage project: a world-class donor health data-asset.

 

The Australian and New Zealand Intensive Care Research Centre

Product usage: TRANSFUSE - Standard Issue Transfusion versus fresher red blood cell use in intensive care - a randomised controlled trial.

Prof DJ (Jamie) Cooper

The Kolling Institute, University of Sydney

Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting

A/Prof Jane Ford, Prof Jonathan Morris, Ms Jillian Patterson

Vision Eye Institute

Product usage: An open label, single arm clinical trial assessing the safety and efficacy of allogeneic 20% serum eye drops in severe dry eye patients.

Dr Colin Chan

 

Institution

Research area and Project

Collaborator(s)

Industry

Australian Defence Force

Product usage: Clip Trial - Cryopreserved versus Liquid Stored Platelets for surgical bleeding.

Prof. Michael Reade

Blood Systems Research Institute

Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, CHIKV, LNV etc.):disease burden and consequences for blood supply safety

Prof. Eric Delwart

CSL

Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing.

Dr Souravi Ghosh, Dr Adrian Zuercher and Dr Bradley Sedgmen

Grifols

Product safety: Does hepatitis E virus pose a risk to the Australian blood supply?

Dr Jerry Holmberg

Macopharma

Product usage: A Phase III prospective, randomised, double-blinded multicentre clinical trial on clinical efficacy and safety of platelet concentrates treated with the Theraflex UV-Platelets system in comparison to conventional platelet components.

 

 

Product safety: Inactivation of Zika virus in plasma and in platelet concentrates following treatment with the THERAFLEX pathogen inactivation (PI) technologies

Dr Stefan Reichenberg, Dr Frank Tolksdorf, Dr Chryslain Sumian

New Health Sciences Inc

Product development and storage: Anaerobic Red Cell storage.

Dr Tatsuro Yoshida

 

Institution

Research area and Project

Collaborator(s)

International

Alberta Health Service Canada

Product safety: What is the risk of alloimmunisation by transfusion of variant RhD red blood cells that serotype as RhD Negative?

 

American Red Cross

Product safety: Does hepatitis E virus pose a risk to the Australian blood supply?

Dr Susan Stramer

Canadian Blood Services

Product development and storage: Characterisation of cryopreserved platelets.

Dr Peter Schubert, Dr Dana Devine

 

Product development and storage: Use of additive solutions for reconstitution of platelets.

Dr Jason Acker

Dartmouth Hitchcock USA

Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets.

Dr Larry Dumont

Environmental Protection Authority, New Zealand

Product safety: What is the risk of alloimmunisation by transfusion of variant RhD red blood cells that serotype as RhD Negative?

Dr Stacy Scott

Fiji National Blood Service of the Republic of Fiji Islands Ministry of Health

Product safety: Building Capacity to solve complex red cell serology using genetic sequencing.

Adriu Sepeti

German Red Cross Blood Service, NTSOB

Product safety: Inactivation of Zika virus in plasma and in platelet concentrates following treatment with the THERAFLEX pathogen inactivation (PI) technologies

Dr Ute Gravemann, Dr Axel Seltsam

McMaster University, Canada

Product usage: A Phase III prospective, randomised, double-blinded multicentre clinical trial on clinical efficacy and safety of platelet concentrates treated with the Theraflex UV-Platelets system in comparison to conventional platelet components.

Nancy Heddle

Netherlands Military Blood Bank

Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets.

Dr Femke Noorman

New Zealand Blood Service

Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets.

Dr Darryl Crimmins

Sanquin

Donor health and wellbeing: Development of an Australian statistical model to predict haemoglobin deferrals.

Dr Mireille Baart

Singapore Defence Medical & Environmental Research Institute

Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets.

Dr Jia Lu

Scottish Blood Transfusion Service

Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets.

Dr Juraj Petrik

University of British Columbia

Product development and storage: Pilot study to determine whether in vitro testing can identify the best donors for our platelet components.

Dr Elisabeth Maurer

University of Ohio

Donor behaviour: Pilot trial of an innovative online intervention with first time O negative donors.

Prof Chris France

University of Ottawa

Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets.

Prof Robert Ben

Back to top